Autosomal dominant polycystic kidney disease.
Cornec-Le Gall E, Alam A, Perrone RD.
Lancet. 2019 Mar 2;393(10174):919-935. doi: 10.1016/S0140-6736(18)32782-X. Epub 2019 Feb 25.
Treatment of Autosomal-Dominant Polycystic Kidney Disease.
Jdiaa SS, Mustafa RA, Yu ASL.
Am J Kidney Dis. 2025 Apr;85(4):491-500. doi: 10.1053/j.ajkd.2024.08.008. Epub 2024 Oct 16.
Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment.
Reiterová J, Tesař V.
Int J Mol Sci. 2022 Mar 19;23(6):3317. doi: 10.3390/ijms23063317.
Therapies in autosomal dominant polycystic kidney disease: beyond tolvaptan.
Fang C, Norouzi S, Garimella PS.
Curr Opin Nephrol Hypertens. 2025 Sep 1;34(5):368-374. doi: 10.1097/MNH.0000000000001101. Epub 2025 Jul 4.
Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025.
Gordon CE, Garimella PS, Perrone RD, Miskulin DC.
Am J Kidney Dis. 2025 Oct;86(4):525-542. doi: 10.1053/j.ajkd.2025.05.010. Epub 2025 Aug 22.
Autosomal Dominant Polycystic Kidney Disease.
Suarez MLG, Titan S, Dahl NK.
Adv Kidney Dis Health. 2024 Nov;31(6):496-503. doi: 10.1053/j.akdh.2024.07.003.
Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances.
Borghol AH, Bou Antoun MT, Hanna C, Salih M, Rahbari-Oskoui FF, Chebib FT.
Ren Fail. 2025 Dec;47(1):2492374. doi: 10.1080/0886022X.2025.2492374. Epub 2025 Apr 23.
Polycystic Kidney/Liver Disease.
Roediger R, Dieterich D, Chanumolu P, Deshpande P.
Clin Liver Dis. 2022 May;26(2):229-243. doi: 10.1016/j.cld.2022.01.009. Epub 2022 Apr 1.
Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update.
Gittus M, Haley H, Harris T, Borrows S, Padmanabhan N, Gale D, Simms R, Williams T, Acquaye A, Wong A, Chan M, Lee E, Ong AC.
BMC Nephrol. 2025 Feb 14;26(1):79. doi: 10.1186/s12882-025-03960-4.
Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease.
Ackley W, Dahl NK, Park M.
Adv Kidney Dis Health. 2023 May;30(3):228-235. doi: 10.1053/j.akdh.2023.02.002.
